account_id none on file
legal_name XORTX Therapeutics Inc.
ticker XRTX
cik 1729214
domain xortx.com
linkedin_company_url https://www.linkedin.com/company/xortx
entry_point_account_id none on file
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 5 executives 1 family 0
why_nownone on file
callsnone on file
filings
On August 4, 2023, the Company announced the appointment of James Fairbairn as Chief Financial Officer to replace Amar Keshri, who left the Company’s employ effective July 31, 2023.
filing / Mar 20, 2026 / receipt
James Fairbairn was appointed Interim Chief Financial Officer effective June 29, 2023. 56 Table of Contents On August 29, 2023, the Company announced that it submitted an ODD application for XORLO™ to the EMA.
filing / Mar 20, 2026 / receipt
During the year ended December 31, 2025, the Company extended its office lease. A $ 88,074 right - of - use asset addition was recognized with a corresponding $ 88,074 increase to the lease liability.
filing / Mar 20, 2026 / receipt
The Company has entered into an office lease expiring in 2026, with an imputed interest rate of 8 % per annum. A reconciliation of the outstanding lease obligation as at December 31, 2025 is as follows:
filing / Mar 20, 2026 / receipt
If sufficient funds on acceptable terms are not available when needed, or at all, we could be forced to significantly reduce operating expenses and delay, scale back or eliminate one or more of our development programs or our business operation.
filing / Mar 20, 2026 / receipt
executives
| Amar Keshri | Chief Financial Officer | receipt |
familynone on file
upcoming
changesnone on file
mcp_package_hint
slug xortx-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$